We are live on ! Find out more
CLSD

Clearside Biomedical
CLSD

Delisted

CLSD was delisted on the 28th of November, 2025.

Back to rankings

67 hedge funds and large institutions have $57.8M invested in Clearside Biomedical in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more call options, than puts

Call options by funds: $2.48M | Put options by funds: $1.48M

57% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 14

19% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 16

3% more funds holding

Funds holding: 65 → 67 (+2)

0.08% more ownership

Funds ownership: 2.27% → 2.35% (+0.08%)

52% less capital invested

Capital invested by funds: $122M → $57.8M (-$63.7M)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

Holders
67
Holders Change
+2
Holders Change %
+3.08%
% of All Funds
1.03%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
19
Increased
22
Reduced
14
Closed
16
Calls
$2.48M
Puts
$1.48M
Net Calls
+$1.01M
Net Calls Change
-$478K

Top Buyers

Rank Fund Capital Flow
1
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$6.98M
2
Morgan Stanley
Morgan Stanley
New York
+$3.45M
3
BlackRock
BlackRock
New York
+$1.79M
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.42M
5
Group One Trading
Group One Trading
Illinois
+$581K

Top Sellers

Rank Fund Capital Flow
1
ACP
Acuta Capital Partners
California
-$7.9M
2
AIIC
AJU IB Investment Company
South Korea
-$1.76M
3
RI
RTW Investments
New York
-$1.73M
4
Invesco
Invesco
Georgia
-$1.66M
5
EI
EAM Investors
California
-$1.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
NFC
26
Northeast Financial Consultants
Connecticut
$146K +$173K +2,666 +307%
Citadel Advisors
27
Citadel Advisors
Florida
$107K -$864K -13,333 -84%
Ameriprise
28
Ameriprise
Minnesota
$106K +$2.14K +33 +1%
WS
29
Wedbush Securities
California
$100K +$156K +2,416 New
CANY
30
Caxton Associates (New York)
New York
$99K -$132K -2,044 -46%
Cambridge Investment Research Advisors
31
Cambridge Investment Research Advisors
Iowa
$88K -$47.3K -730 -26%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$85K – – –
GSEP
33
Golden State Equity Partners
California
$84K +$132K +2,035 New
ECM
34
ExodusPoint Capital Management
New York
$81K +$25.5K +393 +25%
SF
35
Synovus Financial
Georgia
$77K – – –
NDSI
36
Newman Dignan & Sheerar Inc
Rhode Island
$71K +$18.6K +287 +20%
CWM
37
Curi Wealth Management
North Carolina
$68K – – –
PAG
38
Private Advisor Group
New Jersey
$63K – – –
XT
39
XTX Topco
Cayman Islands
$62K +$97.5K +1,505 New
Jane Street
40
Jane Street
New York
$57K +$89.8K +1,386 New
AAS
41
Ameritas Advisory Services
Nebraska
$57K +$89.8K +1,387 New
Charles Schwab
42
Charles Schwab
California
$56K – – –
Stifel Financial
43
Stifel Financial
Missouri
$54K +$18.8K +290 +29%
Balyasny Asset Management
44
Balyasny Asset Management
Illinois
$52K +$81K +1,251 New
OMC
45
Old Mission Capital
Illinois
$45K +$70.7K +1,091 New
IAN
46
Integrated Advisors Network
Texas
$43K – – –
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$40.2K +$63.1K +975 New
VF
48
Virtu Financial
New York
$40K +$63K +972 New
EWA
49
Exencial Wealth Advisors
Oklahoma
$39K +$60.8K +938 New
AGM
50
Alpine Global Management
New York
$38K +$59.3K +916 New
1
2
3 4

CLSD Hedge Fund Activity: Q4 2021 in Review

67 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q4 2021, worth a combined $57.8M — down 52% from $122M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new CLSD positions and 16 closed out — a net gain of 3 holders — while 22 added to existing stakes and 14 trimmed.

The largest buyer was Assenagon Asset Management, adding an estimated $6.98M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $7.9M sold.

  • 67 institutional investors held Clearside Biomedical (CLSD) as of Q4 2021, up from 65 in Q3 2021.
  • Funds reported $57.8M of Clearside Biomedical stock for Q4 2021, down 52% quarter-over-quarter.
  • 19 funds opened new Clearside Biomedical positions in Q4 2021 and 16 closed out, a net change of +3 holders.
  • The largest Clearside Biomedical buyer in Q4 2021 was Assenagon Asset Management, an estimated $6.98M added.
  • The largest Clearside Biomedical seller in Q4 2021 was Acuta Capital Partners, an estimated $7.9M sold.

Based on aggregated 13F filings for Q4 2021.